<b>Introduction:</b> Leukostasis refers to clinical symptoms caused by hyperleukocytosis seen in some haematological diseases such as leukaemia. Cytoreduction can be achieved by therapeutic leukapheresis. The aim of this study was to retrospectively analyse the procedures performed in our Centre and to evaluate their efficacy and safety. <b>Methods:</b> This was a retrospective study of all the therapeutic leukapheresis procedures carried out in our Centre between January 1998 and December 2020. The sample collection was obtained through the review of the clinical files of the respective patients. Statistical analysis was performed using the software R v.4.0.1. A total of 54 therapeutic leukapheresis procedures were performed in 31 patients in our Centre. <b>Results:</b> After these procedures clinical improvement was observed in 16 patients and we verify that there was a significant difference in survival between the group that improved and the group that maintained the same clinical condition or worsened. The lack of immediate clinical improvement was a sign of a poor prognosis. Laboratory efficacy occurred in 16 patients who had a reduction in white blood cell count, with a 39.1% reduction after 24 h, and did not succeed in 15 patients, who had no reduction. However, in this case there is no significant difference in survival between the two groups. There was some complication in 53.9% of the procedures, with hypocalcaemia being the most frequent, which was observed in 22 procedures. Only 4 patients experienced serious side effects but these adverse reactions cannot be attributed to the procedures carried out. The overall survival rate 6 months after this treatment was 51.6%. <b>Conclusion:</b> Despite the reduced number of patients, we conclude that therapeutic leukapheresis is a safe and effective option that may still have a therapeutic role in some cases.

Introduction:The association between cancer and venous thromboembolism is known, and oncology patients present a risk six to seven times higher than the general population of a thrombotic event. Pulmonary embolism is an important cause of morbidity and mortality in this patients group, presenting an underestimated prevalence. Material and Methods:Retrospective study of all episodes of pulmonary embolism referenced in the last five years. We only selected oncologic outpatients and studied their demographics characteristics, risk factors associated with venous thromboembolism, presence of symptoms at diagnosis, risk stratification of venous thromboembolic events by the Khorana model, probability of mortality at 30 days and overall survival. The study is in accordance with the Helsinki declaration. Results: From the 186 patients under evaluation, 55.9% were female, with median age of 64 years. The most prevalent cancers were colorectal (24.2%) and lung (17.7%), most of which had metastases (66.1%) or underwent chemotherapy (69.4%). Pulmonary embolism was a radiological finding in 69.4%, whereas no clinical variable was relevant for the presence or absence of symptoms. Mortality at 30 day resulting from pulmonary embolism was 7.5%, and it was found that symptomatic patients had a lower median survival relative to asymptomatic (12 vs. 20 months, p = 0.029). The retrospective application of the Khorana model to those undergoing chemotherapy identified 11% of individuals at high risk. Discussion: Pulmonary thromboembolism was an imagiological finding in most patients, with no clinical variable able to predict the presence or absence of symptoms. Asymptomatic patients had a higher survival. Conclusions: In our study pulmonary embolism was apparently asymptomatic in most study patients. These data reinforce the need to evaluate the risk of venous thromboembolism in cancer outpatients and consider conducting antithrombotic prophylaxis.

No abstract